Clinical Trials Detalhe
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
General Information
Gender
ALL
Age
from 18 Years to 65 Years
Phase
PHASE3
Study Type
INTERVENTIONAL
Location
Research Site (Braga, Portugal)
Research Site (Coimbra, Portugal)
Research Site (Lisbon, Portugal)
Research Site (Santarém, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT00789854Summary
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.
Conditions
Major Depressive Disorder
Treatment Resistant Depression
Eligibility
Inclusion Criteria: * Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the Diagnostic and Statistical Manual of Mental disorders, 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode * Current episode of depression present, at least 42 days prior to enrolment but not more than 18 months * MADRS-Score ≥ 25 at enrolment and randomisation Exclusion Criteria: * Patients with a DSM-IV Axis I disorder other than MDD within 6 months of randomisation * Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status * Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk, or have made a suicide attempt within the past 6 months